Literature DB >> 22623743

Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis.

Rinat Sergeev1, Caroline Colijn, Megan Murray, Ted Cohen.   

Abstract

The emergence of highly drug-resistant tuberculosis (TB) and interactions between TB and HIV epidemics pose serious challenges for TB control. Previous researchers have presented several hypotheses for why HIV-coinfected TB patients may suffer an increased risk of drug-resistant TB (DRTB) compared to other TB patients. Although some studies have found a positive association between an individual's HIV status and his or her subsequent risk of multidrug-resistant TB (MDRTB), the observed individual-level relationship between HIV and DRTB varies substantially among settings. Here, we develop a modeling framework to explore the effect of HIV on the dynamics of DRTB. The model captures the acquisition of resistance to important classes of TB drugs, imposes fitness costs associated with resistance-conferring mutations, and allows for subsequent restoration of fitness because of compensatory mutations. Despite uncertainty in several key parameters, we demonstrate epidemic behavior that is robust over a range of assumptions. Whereas HIV facilitates the emergence of MDRTB within a community over several decades, HIV-seropositive individuals presenting with TB may, counterintuitively, be at lower risk of drug-resistant TB at early stages of the co-epidemic. This situation arises because many individuals with incident HIV infection will already harbor latent Mycobacterium tuberculosis infection acquired at an earlier time when drug resistance was less prevalent. We find that the rise of HIV can increase the prevalence of MDRTB within populations even as it lowers the average fitness of circulating MDRTB strains compared to similar populations unaffected by HIV. Preferential social mixing among individuals with similar HIV status and lower average CD4 counts among HIV-seropositive individuals further increase the expected burden of MDRTB. This model suggests that the individual-level association between HIV and drug-resistant forms of TB is dynamic, and therefore, cross-sectional studies that do not report a positive individual-level association will not provide assurance that HIV does not exacerbate the burden of resistant TB in the community.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22623743      PMCID: PMC3387814          DOI: 10.1126/scitranslmed.3003815

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  98 in total

1.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

2.  The competitive cost of antibiotic resistance in Mycobacterium tuberculosis.

Authors:  Sebastien Gagneux; Clara Davis Long; Peter M Small; Tran Van; Gary K Schoolnik; Brendan J M Bohannan
Journal:  Science       Date:  2006-06-30       Impact factor: 47.728

3.  Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection.

Authors:  A Guerrero; J Cobo; J Fortún; E Navas; C Quereda; A Asensio; J Cañón; J Blazquez; E Gómez-Mampaso
Journal:  Lancet       Date:  1997-12-13       Impact factor: 79.321

4.  Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: a prospective study.

Authors:  M A Espinal; E N Peréz; J Baéz; L Hénriquez; K Fernández; M Lopez; P Olivo; A L Reingold
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

Review 5.  Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis.

Authors:  Christopher Dye; Brian G Williams; Marcos A Espinal; Mario C Raviglione
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

6.  The effect of human immunodeficiency virus type-1 on the infectiousness of tuberculosis.

Authors:  P Nunn; M Mungai; J Nyamwaya; C Gicheha; R J Brindle; D T Dunn; W Githui; J O Were; K P McAdam
Journal:  Tuber Lung Dis       Date:  1994-02

7.  The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands.

Authors:  I Sutherland; E Svandová; S Radhakrishna
Journal:  Tubercle       Date:  1982-12

8.  Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality.

Authors:  P Nunn; R Brindle; L Carpenter; J Odhiambo; K Wasunna; R Newnham; W Githui; S Gathua; M Omwega; K McAdam
Journal:  Am Rev Respir Dis       Date:  1992-10

9.  Tuberculosis in a rural population of South India: a five-year epidemiological study.

Authors: 
Journal:  Bull World Health Organ       Date:  1974       Impact factor: 9.408

10.  High prevalence of multidrug-resistant tuberculosis, Swaziland, 2009-2010.

Authors:  Elisabeth Sanchez-Padilla; Themba Dlamini; Alexandra Ascorra; Sabine Rüsch-Gerdes; Zerihun Demissie Tefera; Philippe Calain; Roberto de la Tour; Frauke Jochims; Elvira Richter; Maryline Bonnet
Journal:  Emerg Infect Dis       Date:  2012-01       Impact factor: 6.883

View more
  15 in total

1.  The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis.

Authors:  Gwenan M Knight; Caroline Colijn; Sourya Shrestha; Mariam Fofana; Frank Cobelens; Richard G White; David W Dowdy; Ted Cohen
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

2.  Modeling the impact of alternative strategies for rapid molecular diagnosis of tuberculosis in Southeast Asia.

Authors:  Amanda Y Sun; Madhukar Pai; Henrik Salje; Srinath Satyanarayana; Sarang Deo; David W Dowdy
Journal:  Am J Epidemiol       Date:  2013-10-07       Impact factor: 4.897

Review 3.  Antibiotic resistance mechanisms in M. tuberculosis: an update.

Authors:  Liem Nguyen
Journal:  Arch Toxicol       Date:  2016-05-09       Impact factor: 5.153

Review 4.  The potential impact of coinfection on antimicrobial chemotherapy and drug resistance.

Authors:  Ruthie B Birger; Roger D Kouyos; C Jessica E Metcalf; Ted Cohen; Emily C Griffiths; Silvie Huijben; Michael J Mina; Victoriya Volkova; Bryan Grenfell
Journal:  Trends Microbiol       Date:  2015-05-29       Impact factor: 17.079

5.  TB incidence and characteristics in the remote gulf province of Papua New Guinea: a prospective study.

Authors:  Gail B Cross; Katie Coles; Mandana Nikpour; Owen A Moore; Justin Denholm; Emma S McBryde; Damon P Eisen; Beverlyn Warigi; Robyn Carter; Sushil Pandey; Paul Harino; Peter Siba; Christopher Coulter; Ivo Mueller; Suparat Phuanukoonnon; Marc Pellegrini
Journal:  BMC Infect Dis       Date:  2014-02-20       Impact factor: 3.090

Review 6.  Molecular biology of drug resistance in Mycobacterium tuberculosis.

Authors:  Tasha Smith; Kerstin A Wolff; Liem Nguyen
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 7.  How can mathematical models advance tuberculosis control in high HIV prevalence settings?

Authors:  R M G J Houben; D W Dowdy; A Vassall; T Cohen; M P Nicol; R M Granich; J E Shea; P Eckhoff; C Dye; M E Kimerling; R G White
Journal:  Int J Tuberc Lung Dis       Date:  2014-05       Impact factor: 2.373

8.  First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea.

Authors:  Mebrat Ejo; Florian Gehre; Mamadou Dian Barry; Oumou Sow; Nene Mamata Bah; Mory Camara; Boubacar Bah; Cecile Uwizeye; Elie Nduwamahoro; Kristina Fissette; Pim De Rijk; Corinne Merle; Piero Olliaro; Marcos Burgos; Christian Lienhardt; Leen Rigouts; Bouke C de Jong
Journal:  Infect Genet Evol       Date:  2015-05-21       Impact factor: 3.342

9.  The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis.

Authors:  Kuldeep Singh Sachdeva; Neeraj Raizada; Radhey Shyam Gupta; Sreenivas Achuthan Nair; Claudia Denkinger; Chinnambedu Nainarappan Paramasivan; Shubhangi Kulsange; Rahul Thakur; Puneet Dewan; Catharina Boehme; Nimalan Arinaminpathy
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

10.  Type-specific human papillomavirus biological features: validated model-based estimates.

Authors:  Iacopo Baussano; K Miriam Elfström; Fulvio Lazzarato; Anna Gillio-Tos; Laura De Marco; Francesca Carozzi; Annarosa Del Mistro; Joakim Dillner; Silvia Franceschi; Guglielmo Ronco
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.